KRAS and colorectal cancer: A greater understanding of colorectal cancer biology followed by use of EGFR-targeted treatments has led to discovery of the importance of BRAF, PIK3CA, KRAS, and NRAS mutations in predicting a lack of response to EGFR-targeted therapy.1